Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Novel Therapeutic Strategies for Cardiorenal Protection in Patients with Type 2 Diabetes and Chronic Kidney Disease

Author(s): Panagiotis I. Georgianos, Stefanos Roumeliotis, Theodoros Eleftheriadis and Vassilios Liakopoulos*

Volume 20, Issue 2, 2022

Published on: 29 October, 2021

Page: [117 - 120] Pages: 4

DOI: 10.2174/1570161119666211029111428

« Previous Next »
[1]
Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015; 385(9981): 1975-82.
[http://dx.doi.org/10.1016/S0140-6736(14)61601-9] [PMID: 25777665]
[2]
Debella YT, Giduma HD, Light RP, Agarwal R. Chronic kidney disease as a coronary disease equivalent--a comparison with diabetes over a decade. Clin J Am Soc Nephrol 2011; 6(6): 1385-92.
[http://dx.doi.org/10.2215/CJN.10271110] [PMID: 21393492]
[3]
Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380(9844): 807-14.
[http://dx.doi.org/10.1016/S0140-6736(12)60572-8] [PMID: 22717317]
[4]
Georgianos PI, Vaios V, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Mechanisms for cardiorenal protection of SGLT-2 inhibitors. Curr Pharm Des 2021; 27(8): 1043-50.
[http://dx.doi.org/10.2174/1381612827666210119102409] [PMID: 33463454]
[5]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[6]
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347-57.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[7]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[8]
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295-306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]
[9]
9. American Diabetes Association 11. Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabetes Care 2019; 42(Suppl. 1): S124-38.
[http://dx.doi.org/10.2337/dc19-S011] [PMID: 30559237]
[10]
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436-46.
[http://dx.doi.org/10.1056/NEJMoa2024816] [PMID: 32970396]
[11]
Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021; 42(2): 152-61.
[http://dx.doi.org/10.1093/eurheartj/ehaa736] [PMID: 33099609]
[12]
Chung EY, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2020; 10: CD007004.
[PMID: 33107592]
[13]
Savarese G, Carrero JJ, Pitt B, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 2018; 20(9): 1326-34.
[http://dx.doi.org/10.1002/ejhf.1182] [PMID: 29578280]
[14]
Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int 2018; 93(2): 325-34.
[http://dx.doi.org/10.1016/j.kint.2017.08.038] [PMID: 29276100]
[15]
FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes. 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability
[16]
Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383(23): 2219-29.
[http://dx.doi.org/10.1056/NEJMoa2025845] [PMID: 33264825]
[17]
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021.
[http://dx.doi.org/10.1056/NEJMoa2110956] [PMID: 34449181]
[18]
Perkovic V, Agarwal R, Fioretto P, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016; 90(6): 1175-83.
[http://dx.doi.org/10.1016/j.kint.2016.09.010] [PMID: 27884312]

Rights & Permissions Print Cite
Article Metrics
39
1
© 2024 Bentham Science Publishers | Privacy Policy